BR0215560A - Derivados de 2'-halo-3',5'-dialcoxifen-1'-il-imino-2-imidazolidina e o seu uso para o tratamento de incontinência urinária - Google Patents

Derivados de 2'-halo-3',5'-dialcoxifen-1'-il-imino-2-imidazolidina e o seu uso para o tratamento de incontinência urinária

Info

Publication number
BR0215560A
BR0215560A BR0215560-5A BR0215560A BR0215560A BR 0215560 A BR0215560 A BR 0215560A BR 0215560 A BR0215560 A BR 0215560A BR 0215560 A BR0215560 A BR 0215560A
Authority
BR
Brazil
Prior art keywords
halo
imino
treatment
urinary incontinence
dialkoxyphen
Prior art date
Application number
BR0215560-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Franz Esser
Pascale Pouzet
Naoki Ishiguro
Hisato Kitagawa
Ikunobu Muramatsu
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0215560A publication Critical patent/BR0215560A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/50Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0215560-5A 2002-01-31 2002-12-16 Derivados de 2'-halo-3',5'-dialcoxifen-1'-il-imino-2-imidazolidina e o seu uso para o tratamento de incontinência urinária BR0215560A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002352A EP1333028A1 (en) 2002-01-31 2002-01-31 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
PCT/EP2002/014299 WO2003064398A1 (en) 2002-01-31 2002-12-16 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence

Publications (1)

Publication Number Publication Date
BR0215560A true BR0215560A (pt) 2004-12-21

Family

ID=8185397

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215560-5A BR0215560A (pt) 2002-01-31 2002-12-16 Derivados de 2'-halo-3',5'-dialcoxifen-1'-il-imino-2-imidazolidina e o seu uso para o tratamento de incontinência urinária

Country Status (20)

Country Link
EP (2) EP1333028A1 (enExample)
JP (1) JP2005516066A (enExample)
KR (1) KR20040074134A (enExample)
CN (1) CN1617857A (enExample)
AR (1) AR038380A1 (enExample)
BR (1) BR0215560A (enExample)
CA (1) CA2474588A1 (enExample)
EA (1) EA200400877A1 (enExample)
EC (1) ECSP045210A (enExample)
HR (1) HRP20040691A2 (enExample)
HU (1) HUP0402654A2 (enExample)
IL (1) IL162776A0 (enExample)
MX (1) MXPA04007250A (enExample)
NO (1) NO20043614L (enExample)
PE (1) PE20030819A1 (enExample)
PL (1) PL369826A1 (enExample)
TW (1) TW200418462A (enExample)
UY (1) UY27628A1 (enExample)
WO (1) WO2003064398A1 (enExample)
ZA (1) ZA200405173B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
BRPI0912604A2 (pt) * 2008-05-13 2019-09-10 Allergan Inc quinolinilmetilimidazóis como agentes terapêuticos
BRPI0913019A2 (pt) 2008-05-13 2015-10-13 Allergan Inc naftilmetilimidazóis para o tratamento de incontinência urinária por estresse
ES2665293T3 (es) * 2008-06-09 2018-04-25 Allergan, Inc. Compuesto para tratar estados con mediación alfa-adrenérgica
US8063231B2 (en) * 2008-06-09 2011-11-22 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
US9034910B2 (en) 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2220906A1 (de) * 1972-04-28 1973-11-15 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline-(2), deren saeureadditionssalze sowie verfahren zu deren herstellung
DE2259160A1 (de) * 1972-12-02 1974-06-06 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel
AT333749B (de) * 1974-07-03 1976-12-10 Chemie Linz Ag Verfahren zur herstellung von neuen 2-arylamino-2-imidazolinderivaten
MTP837B (en) * 1977-11-07 1979-10-22 Hoffman La Roche And Co Aktien Derivatives 2 finino-imidazolidire
DE3514351A1 (de) * 1985-04-20 1986-11-06 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte 2-(n-alkinyl-n-phenyl)amino)-imidazolinderivate, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
DE19740176C2 (de) * 1997-09-12 2000-04-06 Lemfoerder Metallwaren Ag Handschaltvorrichtung für ein Kraftfahrzeug

Also Published As

Publication number Publication date
UY27628A1 (es) 2003-08-29
CA2474588A1 (en) 2003-08-07
AR038380A1 (es) 2005-01-12
KR20040074134A (ko) 2004-08-21
CN1617857A (zh) 2005-05-18
ZA200405173B (en) 2005-06-21
TW200418462A (en) 2004-10-01
HRP20040691A2 (en) 2004-12-31
NO20043614L (no) 2004-08-30
ECSP045210A (es) 2004-09-28
EP1472231A1 (en) 2004-11-03
EP1333028A1 (en) 2003-08-06
JP2005516066A (ja) 2005-06-02
HUP0402654A2 (hu) 2005-03-29
IL162776A0 (en) 2005-11-20
WO2003064398A1 (en) 2003-08-07
PE20030819A1 (es) 2003-10-20
EA200400877A1 (ru) 2005-02-24
PL369826A1 (en) 2005-05-02
MXPA04007250A (es) 2004-10-29

Similar Documents

Publication Publication Date Title
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BRPI0510284A (pt) derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv
BRPI0412348A (pt) derivados de piperazina e seu uso como agentes terapêuticos
TW200716139A (en) Methods and compositions for managing psychotic disorders
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
BR0209153A (pt) Indol, azaindol e derivados de amidopiperazina heterocìclicos relacionados
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
BRPI0408437A (pt) derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
BR9906169A (pt) Derivados de pirrolo [1, 2-a] pirazina como ligandos sht 1a
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
UA94065C2 (en) Dihydropseudoerythromycin derivatives
BR0212031A (pt) Preparados de combinação de derivados de 1,1-dióxido de 1-4-benzotiepina com outras substâncias ativas e seu emprego
BR0113925A (pt) Derivados de ácido 2-amino-2-alquil-5 heptenóico e heptinóico úteis como inibidores da sintase de óxido nìtrico
ATE420639T1 (de) Antimykotische mittel
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
ATE240956T1 (de) Haloalkoxy-imidazonaphthyridine
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0410050A (pt) método de tratamento ou de profilaxia de distúrbios psicóticos, distúrbios de prejuìzo intelectual ou doenças ou condições nos quais a modulação do receptor alfa7-nicotìnico é benéfica, composição farmacêutica, método de tratamento ou de profilaxia de doenças, uso de um composto, composto, e, método de preparação de um composto
BR0215560A (pt) Derivados de 2'-halo-3',5'-dialcoxifen-1'-il-imino-2-imidazolidina e o seu uso para o tratamento de incontinência urinária
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR9712308A (pt) Inibidor de catarata secundária
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]